A new or worse cough or breathlessness during cancer drug treatment should be reported straight away. Your team first looks for a cause that can be treated, such as infection, a clot, fluid, anaemia or lung inflammation from the drug. Some drugs have their own rules for pausing or stopping. A hand-held fan, breathing techniques and sometimes low-dose morphine can ease breathlessness that remains.
Scope. This page joins three kinds of source that answer different questions. The product labels say what to do about a breathing symptom on a named drug. The ESMO 2020 guideline covers breathlessness in patients with cancer in general, and the ASCO 2021 guideline covers dyspnoea in adults with advanced cancer; neither is written for a side effect of a particular drug. The CHEST 2017 guideline covers cough in adults with lung cancer that persists despite cancer treatment. Local protocols come first.
Cause first. ESMO: clinicians should identify and treat any potentially reversible condition contributing to breathlessness (II, A*); its table lists anaemia, asthma or COPD, heart failure, pleural and pericardial effusion, pneumonia, pulmonary embolism, superior vena cava syndrome, and pulmonary toxicity from chemotherapy or immunotherapy (withhold treatment and consider corticosteroids).
Product rules read. Atezolizumab and durvalumab (US labels): in suspected immune-mediated reactions, start a workup to exclude alternative causes, including infection; pneumonitis is then managed by grade (see the pneumonitis protocol). Sotorasib (US label and EU SmPC): immediately withhold for suspected ILD or pneumonitis and permanently discontinue if no other cause is identified. Adagrasib (US label): withhold, without the word immediately; the EU SmPC has no ILD warning and lists pneumonitis as a common adverse reaction. Zenocutuzumab (US label): immediately withhold, corticosteroids as clinically indicated, permanently discontinue for confirmed grade 2 or higher. Belzutifan: monitor oxygen saturation before and periodically during treatment; the US label acts on a pulse oximeter reading below 88% with exercise (consider withholding) or at rest (withhold), the EU SmPC on CTCAE grade, with grade 3 defined by the same resting reading (grade 3 without symptoms: consider supplemental oxygen and continuing or withholding). Dasatinib: the EU SmPC asks that dyspnoea and fatigue be evaluated for pleural effusion, pulmonary oedema, anaemia or lung infiltration, with the dose reduced or interrupted meanwhile, and that pulmonary arterial hypertension be considered if nothing is found; the US label asks for a prompt chest x-ray or other imaging for symptoms of pleural effusion such as new or worsened dyspnoea or dry cough; both labels stop dasatinib permanently if it is confirmed. Carfilzomib (both): evaluate dyspnoea to exclude cardiac failure and pulmonary syndromes, and stop for grade 3 or 4 until resolved. Pazopanib: the EU SmPC asks for close observation for pneumothorax; the US label reports it in 3.3% of people in the sarcoma trial and gives no instruction beyond counselling.
Symptom. ESMO: consider a hand-held fan (II, B), teach breathing techniques, pacing and positions (II, B), palliative oxygen is not recommended at a resting SpO2 of 90% or more (II, D), regular low-dose oral morphine is the first-line drug for severe chronic breathlessness that persists despite non-drug measures (II, B), and benzodiazepines should not be first-line (III, D). The ASCO abstract agrees on the order and says systemic opioids should be offered when non-drug measures give inadequate relief. CHEST, for cough in lung cancer: assess for co-existing causes, then cough suppression exercises, a demulcent linctus, then an opioid derivative (Grade 2C).
Why: This is the counselling the US labels for atezolizumab and durvalumab ask for, because these drugs can cause pneumonitis. The US labels for adagrasib and zenocutuzumab ask the same for new or worsening respiratory symptoms, and the belzutifan label for signs of low oxygen. Macmillan tells patients to contact their doctor straight away if breathlessness is a new symptom, if it hurts to breathe, or if breathlessness gets worse quickly.
“Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, or shortness of breath”
Genentech, a member of the Roche Group (manufacturer); FDA label via DailyMed 2026
Why: ESMO explains that breathlessness is easily overlooked in someone sitting at rest, because people avoid the activity that brings it on, so the answer to 'are you short of breath' is often no. ESMO asks for this screening at every inpatient and outpatient encounter for patients with cancer; it is not a rule written for a particular drug.
“Routine screening for breathlessness should include a unidimensional scale of choice and activities that patients have stopped or reduced because of breathlessness”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · III, B*
Why: ESMO says breathlessness may be related to cancer progression, cancer therapies or acute complications such as infections or pulmonary embolism, and that existing conditions such as COPD and heart failure may add to it. Its table of treatable conditions also lists anaemia, pleural and pericardial effusion, pneumonia, superior vena cava syndrome, and lung toxicity from chemotherapy or immunotherapy, for which it says to withhold treatment and consider corticosteroids.
“Clinicians should identify and treat any potentially reversible condition(s) contributing to breathlessness”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · II, A*
Why: The US labels for both drugs say they can cause immune-mediated pneumonitis and give this instruction for any suspected immune-mediated reaction. The EU SmPC for atezolizumab says causes other than immune-mediated pneumonitis should be ruled out. Cough is listed as a very common adverse reaction of both drugs in the EU SmPCs, so not every cough is pneumonitis; the labels read give no rule for telling the two apart other than the workup.
“In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection.”
Genentech, a member of the Roche Group (manufacturer); FDA label via DailyMed 2026
Why: The US label reports ILD or pneumonitis in 2.2% of people, with one fatal case, and names dyspnoea, cough and fever as the symptoms to monitor for; it also lists cough among the most common adverse reactions. The EU SmPC gives the same rule. For adagrasib the US label says withhold (without 'immediately') and permanently discontinue if no other cause is identified; the EU SmPC for adagrasib has no warning on the subject. For zenocutuzumab the US label says immediately withhold, give corticosteroids as clinically indicated, and permanently discontinue if grade 2 or higher is confirmed. The interstitial lung disease protocol covers what follows.
“Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified”
Why: The US label says belzutifan can cause severe hypoxia that may require discontinuation, supplemental oxygen or hospitalisation. The EU SmPC asks for the same monitoring and names pulse oximetry as the method. Neither label states how often 'periodically' is.
“Monitor oxygen saturation before initiation of, and periodically throughout, treatment with WELIREG.”
Merck Sharp & Dohme (manufacturer); FDA label via DailyMed 2026
Why: The US label defines low saturation by example as a pulse oximeter reading below 88% or a PaO2 of 55 mm Hg or less, and for a fall with exercise only says to consider withholding until the reading with exercise is above 88%. The EU SmPC is organised by CTCAE grade and symptoms instead, and its table gives the same example for grade 3 (a pulse oximeter reading below 88% or a PaO2 of 55 mm Hg or less at rest): for grade 3 hypoxia without symptoms, giving supplemental oxygen and continuing or withholding should be considered; for grade 3 with symptoms, withhold, treat the hypoxia and resume at a reduced dose; if symptomatic hypoxia keeps recurring, discontinue; for grade 4, permanently discontinue. Neither label gives a reason for its thresholds.
“For life-threatening hypoxia or for recurrent symptomatic hypoxia, permanently discontinue WELIREG”
Merck Sharp & Dohme (manufacturer); FDA label via DailyMed 2026
Why: This is the EU SmPC's rule. The US label has no single sequence. Under pulmonary arterial hypertension it asks for evaluation for signs and symptoms of underlying cardiopulmonary disease before and during treatment. Under fluid retention it asks that symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnoea on exertion or at rest, pleuritic chest pain or dry cough, be evaluated promptly with a chest x-ray or other imaging as appropriate, and says to consider dose reduction or treatment interruption. Pleural effusion on dasatinib has its own page.
“Patients who develop dyspnoea and fatigue after initiation of therapy should be evaluated for common etiologies including pleural effusion, pulmonary oedema, anaemia, or lung infiltration.”
Bristol-Myers Squibb (marketing authorisation holder); European Medicines Agency 2026
Why: Both labels say pulmonary arterial hypertension has been reported at any time after starting, including after more than a year of treatment, and that it may improve after dasatinib is stopped. The US label lists dyspnoea, fatigue, hypoxia and fluid retention as how it shows itself and gives the same permanent stop. The EU SmPC describes the reported cases as confirmed by right heart catheterisation and leaves the diagnostic approach to standard practice guidelines.
“If no explanation is found, or if there is no improvement with dose reduction or interruption, the diagnosis of PAH should be considered. The diagnostic approach should follow standard practice guidelines. If PAH is confirmed, dasatinib should be permanently discontinued.”
Bristol-Myers Squibb (marketing authorisation holder); European Medicines Agency 2026
Why: The US label reports dyspnoea in 25% of people treated, grade 3 or greater in 4%; the EU SmPC gives the same rule. The two differ on drug-induced lung toxicity (the US label says discontinue; the EU SmPC says stop until resolved and consider restarting on a benefit and risk assessment) and agree on pulmonary hypertension (withhold until resolved or back to baseline, then consider restarting).
“Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop Kyprolis for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart Kyprolis based on a benefit/risk assessment”
Onyx Pharmaceuticals and Amgen (manufacturer); FDA label via DailyMed 2025
Why: The EU SmPC says pneumothorax occurred in the trials in advanced soft tissue sarcoma. The US label reports it in 8 of 240 people (3.3%) in the sarcoma trial and 2 of 290 (0.7%) in the kidney cancer trial, has no warning section on it, and asks only that patients be advised to report new onset of dyspnoea, chest pain or localised limb oedema. Neither says how a pneumothorax on pazopanib should be treated or whether the drug should be paused. Separately, both say pazopanib should be discontinued in anyone who develops interstitial lung disease or pneumonitis.
“Patients on pazopanib treatment should be observed closely for signs and symptoms of pneumothorax.”
Novartis (marketing authorisation holder); European Medicines Agency 2025
Why: ESMO's panel supports a fan whatever the oxygen saturation, given its potential benefit and lack of harm, and describes the experimental evidence as limited: six of ten studies reported a significant improvement. The ASCO abstract says airflow interventions such as a fan directed at the cheek may be offered. ESMO writes for patients with cancer and ASCO for advanced cancer; neither tested a fan for a drug side effect.
“Consider use of a hand-held fan directed to the face and inform patients of the potential mechanisms and benefit. This may be useful alone in people without hypoxaemia, or as an adjunct to those requiring oxygen supplementation for hypoxaemia”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · II, B
Why: ESMO says patients should be assured that being breathless is itself not dangerous and that it settles with rest, and describes leaning forward, relaxed sitting and high side lying as positions often recommended. Breathing retraining carries the same grade in a separate ESMO recommendation.
“Educate and inform patients on strategies including activity pacing, relieving positions and distraction techniques to encourage self-management”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · II, B
Why: ESMO says oxygen has not been consistently shown to relieve breathlessness in people with mild or no hypoxaemia, citing a trial of 239 people in which oxygen was no better than room air over 7 days, and recommends a saturation below 90% as the cut-off for clinically relevant hypoxaemia. It adds that a trial of oxygen could be justified in chronic breathlessness that persists despite other treatments, reviewed within a few days and stopped if the person perceives no benefit. The ASCO abstract says standard supplemental oxygen may be offered for patients with hypoxaemia. These are rules for the symptom; on belzutifan a low reading is a side effect with its own label rules (above).
“Palliative oxygen is not recommended in patients with resting SpO2 ≥90%”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · II, D
Why: ESMO says a starting dose of 10 to 30 mg of scheduled morphine over 24 hours can be used in people who have not had opioids (II, B), adjusted to the person's symptoms, and describes the overall evidence as low: in a Cochrane review opioids lowered breathlessness by 0.8 points on a 0 to 10 scale. The ASCO abstract says systemic opioids should be offered to patients with inadequate relief from non-drug measures, and that support for drug treatments was limited. ESMO says benzodiazepines should not be the first drug because of the risk of sedation and delirium (III, D). Both guidelines address chronic breathlessness; neither addresses a sudden symptom on a new drug, where the cause is sought first.
“Regular, oral, low-dose morphine is the first-line pharmacological treatment for severe chronic breathlessness, which persists despite non-pharmacological measures”
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · II, B
Why: CHEST suggests this as the first step and gives it no grade. Its guideline covers cough in adults with lung cancer that remains bothersome despite surgery, chemotherapy or radiotherapy; it notes that lung cancer treatments can themselves cause cough and says it focuses on cough beyond anticancer treatments. Its table of causes of cough in people with cancer includes pleural effusion, chest infection, COPD, gastro-oesophageal reflux disease, heart failure, cough after radiation or chemotherapy, and ACE inhibitor medicines. No guideline on cough as a side effect of a targeted drug or immunotherapy was found.
“In adult patients with cough associated with lung cancer that persists despite cancer treatment, we suggest, as a first step, that a comprehensive assessment according to a published, evidence-based management guideline be undertaken to identify any co-existing causes linked with cough and initiate treatment accordingly”
Chest (American College of Chest Physicians, sole supporter) 2017 · Ungraded, Consensus Based Statement
Why: CHEST calls this a step-up approach and describes the evidence as primarily low quality: the review behind it found 17 trials. It suggests cough suppression exercises as an alternative or addition to drugs, a demulcent first because of low cost, some evidence of effect and few side effects, and says opioids are the drugs with most evidence for cough in lung cancer. All three suggestions are graded 2C.
“In adult patients with lung cancer experiencing cough that does not respond to demulcents, we suggest pharmacological management using an opiate-derivative titrated to an acceptable side-effect profile”
Chest (American College of Chest Physicians, sole supporter) 2017 · Grade 2C
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No guideline that could be found addresses breathlessness or cough as a side effect of an anticancer drug as a subject in its own right. The best-supported approach joins two things. First, the cause: ESMO 2020 asks that any reversible condition be identified and treated (II, A*), and each label read sets its own rule for its drug, which for sotorasib, adagrasib, zenocutuzumab and the checkpoint inhibitors means treating the symptom as possible lung inflammation until other causes are excluded, for belzutifan means measuring oxygen saturation, for dasatinib means looking for effusion, oedema, anaemia and infiltrates and then for pulmonary arterial hypertension, and for carfilzomib means excluding heart failure. Where the US label and the EU SmPC differ (belzutifan, dasatinib, carfilzomib lung toxicity, pazopanib pneumothorax, adagrasib) both are shown. Second, the symptom: ESMO 2020, read in full, asks clinicians to consider a fan (II, B) and recommends self-management and breathing techniques (II, B), exercise-based rehabilitation (I, A), low-dose morphine for severe chronic breathlessness that persists (II, B), no oxygen at a resting saturation of 90% or more (II, D), and referral to a breathlessness service where one exists (I, A). The ASCO 2021 abstract, for advanced cancer, describes the same order: assessment, reversible causes, palliative care referral, non-drug measures, then systemic opioids. For cough, CHEST 2017 is a guideline for lung cancer, with every graded suggestion at 2C.
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · Journal of Clinical Oncology (American Society of Clinical Oncology) 2021 · Chest (American College of Chest Physicians, sole supporter) 2017 · Merck Sharp & Dohme (manufacturer); FDA label via DailyMed 2026 · Merck Sharp & Dohme (marketing authorisation holder); European Medicines Agency 2026 · Bristol-Myers Squibb (manufacturer); FDA label via DailyMed 2026 · Bristol-Myers Squibb (marketing authorisation holder); European Medicines Agency 2026 · Onyx Pharmaceuticals and Amgen (manufacturer); FDA label via DailyMed 2025 · Amgen (marketing authorisation holder); European Medicines Agency 2026 · Amgen (manufacturer); FDA label via DailyMed 2025 · Amgen (marketing authorisation holder); European Medicines Agency 2026
Where it differs: ESMO, for patients with cancer: consider a fan (II, B); morphine is first-line for severe chronic breathlessness that persists despite non-drug measures (II, B); benzodiazepines should not be first-line (III, D) and may be used with caution for breathlessness with anxiety if opioids are not effective (V, C); palliative oxygen is not recommended at a resting saturation of 90% or more (II, D); corticosteroids may be considered for cancer-related breathlessness refractory to other treatments (II, C). ASCO, for adults with advanced cancer, as far as its abstract goes: airflow interventions such as a fan may be offered; standard supplemental oxygen may be offered for patients with hypoxaemia; systemic opioids should be offered when non-drug measures give inadequate relief; corticosteroids and benzodiazepines are 'also discussed', with no position stated in the abstract. No disagreement is visible in the abstract; the full ASCO recommendations and their strengths were not read.
Evidence: ESMO grades as printed above. ASCO: the abstract reports a systematic review of 48 randomised trials and two retrospective cohort studies, and says support for pharmacologic interventions was limited; it prints no grade.
ESMO Open (European Society for Medical Oncology; no external funding) 2020 · Journal of Clinical Oncology (American Society of Clinical Oncology) 2021
Where it differs: The US label is organised by where the low reading occurs: with exercise (pulse oximeter below 88%), consider withholding until the reading with exercise is above 88%, then resume at the same or a reduced dose; at rest (below 88%, or PaO2 55 mm Hg or less) or where urgent intervention is indicated, withhold until resolved and resume at a reduced dose or discontinue; life-threatening or recurrent symptomatic hypoxia, permanently discontinue. The EU SmPC is organised by CTCAE grade and symptoms, with grade 3 defined by the same example as the US label's resting rule (pulse oximeter below 88%, or PaO2 55 mm Hg or less, at rest): grade 3 without symptoms, an option to continue or withhold, with supplemental oxygen to be considered; grade 3 with symptoms, withhold, treat and resume at a dose reduced by 40 mg or discontinue; grade 4, permanently discontinue. The EU SmPC has no separate rule for a fall with exercise only.
Evidence: Regulatory labels; not graded. The US label reports hypoxia in 15% of patients in the LITESPARK-005 trial, 10% at grade 3; the EU SmPC reports it in 15% of patients with advanced kidney cancer, 10% at grade 3.
Merck Sharp & Dohme (manufacturer); FDA label via DailyMed 2026 · Merck Sharp & Dohme (marketing authorisation holder); European Medicines Agency 2026
Where it differs: The EU SmPC sets out a sequence: echocardiography at the start in every patient with symptoms of cardiac disease, and considered in those with risk factors for cardiac or pulmonary disease; evaluation of dyspnoea and fatigue for common causes with the dose reduced or interrupted meanwhile; pulmonary arterial hypertension considered if nothing is found or there is no improvement; permanent discontinuation if confirmed. The US label says to evaluate for signs and symptoms of underlying cardiopulmonary disease before and during treatment and to discontinue permanently if pulmonary arterial hypertension is confirmed, without the intermediate steps or any mention of echocardiography. Its separate fluid retention warning asks for a prompt chest x-ray or other imaging for new or worsened dyspnoea, pleuritic chest pain or dry cough, and says to consider dose reduction or treatment interruption.
Evidence: Regulatory labels; not graded. The EU SmPC lists pulmonary arterial hypertension as uncommon.
Bristol-Myers Squibb (manufacturer); FDA label via DailyMed 2026 · Bristol-Myers Squibb (marketing authorisation holder); European Medicines Agency 2026
Where it differs: For drug-induced pulmonary toxicity (acute respiratory distress syndrome, acute respiratory failure, pneumonitis, interstitial lung disease) the US label says discontinue carfilzomib. The EU SmPC says evaluate and stop until resolved, and consider whether to restart on a benefit and risk assessment. For dyspnoea and for pulmonary hypertension the two give the same rule.
Evidence: Regulatory labels; not graded.
Onyx Pharmaceuticals and Amgen (manufacturer); FDA label via DailyMed 2025 · Amgen (marketing authorisation holder); European Medicines Agency 2026
Where it differs: Sotorasib (US and EU): immediately withhold when suspected; permanently discontinue if no other cause is identified. Adagrasib (US): withhold when suspected; permanently discontinue if no other cause is identified. Adagrasib (EU SmPC): no warning or dose rule; pneumonitis is listed as a common adverse reaction. Zenocutuzumab (US): immediately withhold and give corticosteroids as clinically indicated; permanently discontinue if grade 2 or higher is confirmed.
Evidence: Regulatory labels; not graded.
Amgen (manufacturer); FDA label via DailyMed 2025 · Amgen (marketing authorisation holder); European Medicines Agency 2026 · Mirati Therapeutics, a Bristol Myers Squibb company (manufacturer); FDA label via DailyMed 2026 · Bristol-Myers Squibb (marketing authorisation holder); European Medicines Agency 2026 · Partner Therapeutics (labeller); FDA label via DailyMed 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Identify and treat any potentially reversible condition contributing to breathlessness “Clinicians should identify and treat any potentially reversible condition(s) contributing to breathlessness” | II, A* | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| A hand-held fan directed to the face | II, B | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Breathing retraining techniques, or referral to a physiotherapist “Advise patients on relevant breathing retraining techniques and/or refer to specialist services such as a physiotherapist” | II, B | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Regular low-dose oral morphine as the first-line drug for severe chronic breathlessness that persists despite non-drug measures | II, B | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| A laxative offered to everyone starting an opioid, and an antiemetic as needed “All patients starting opioids should be offered prophylaxis for constipation with laxatives and, as needed, antiemetics” | I, A | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Benzodiazepines not to be used first-line for breathlessness “Because of significant risk of sedation and delirium, benzodiazepines should not be used for breathlessness as first-line pharmacological therapy” | III, D | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Benzodiazepines with caution for breathlessness with anxiety if opioids are not effective “Benzodiazepines may be used with caution in patients with cancer for the relief of breathlessness with associated anxiety if opioids are not effective” | V, C | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| No palliative oxygen at a resting saturation of 90% or more | II, D | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Corticosteroids may be considered for cancer-related breathlessness refractory to other treatments “Corticosteroids may be considered for palliation of cancer-related breathlessness refractory to other treatments” | II, C | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Referral to a specialist multimodal breathlessness service if available “Patients with cancer with chronic breathlessness should be referred to specialist multimodal breathlessness services if available” | I, A | ESMO Open (European Society for Medical Oncology; no external funding) 2020 |
| Systemic opioids should be offered when non-drug measures give inadequate relief (advanced cancer) “For patients who derive inadequate relief from nonpharmacologic interventions, systemic opioids should be offered.” | No grade printed in the abstract; the full text was not read | Journal of Clinical Oncology (American Society of Clinical Oncology) 2021 |
| A fan, supplemental oxygen for hypoxaemia and self-management approaches may be offered (advanced cancer) “Nonpharmacologic interventions that may be offered to relieve dyspnea include airflow interventions (eg, a fan directed at the cheek), standard supplemental oxygen for patients with hypoxemia, and other psychoeducational, self-management, or complementary approaches.” | No grade printed in the abstract; the full text was not read | Journal of Clinical Oncology (American Society of Clinical Oncology) 2021 |
| Assessment for co-existing causes as the first step for persistent cough in lung cancer | Ungraded, Consensus Based Statement | Chest (American College of Chest Physicians, sole supporter) 2017 |
| Cough suppression exercises as an alternative or addition to drugs, where available “In adult patients with lung cancer experiencing cough despite anticancer treatment, we suggest cough suppression exercises as alternative or additional to pharmacological therapy where such services are available” | Grade 2C | Chest (American College of Chest Physicians, sole supporter) 2017 |
| An opioid derivative for cough that does not respond to demulcents | Grade 2C | Chest (American College of Chest Physicians, sole supporter) 2017 |
Shares Immune-related pneumonitis from checkpoint inhibitors, by grade, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Atezolizumab and the tags protocol, acute-oncology.
Shares Immune-related pneumonitis from checkpoint inhibitors, by grade, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Atezolizumab and the tags protocol, acute-oncology.
Shares Superior vena cava obstruction and the tags protocol, acute-oncology.
Shares Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading, American Society of Clinical Oncology (ASCO) and the tags protocol, acute-oncology.
Shares Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading and the tags protocol, acute-oncology.
Shares Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading and the tags protocol, acute-oncology.
Shares Immune-related pneumonitis from checkpoint inhibitors, by grade, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Atezolizumab and the tags protocol, acute-oncology.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Atezolizumab, Durvalumab and the tags protocol, acute-oncology.